Investor Presentation for the quarter and half year ended September 30, 2026

November 05, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 66/26-27 Our Reference No. 66/26-27 Dear Sir/ Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation – Q2 FY 26-27. You are requested to take the same on record. Thanking You. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Encl: As above Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E:complianceofficer@glenmarkpharma.com Investor Presentation Q2 FY27 05 November 2026 Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, futureevents or performance and underlying assumptions and otherstatements that are other thanstatements of historical fact, including, but not limitedto, those that areidentifiedbythe use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects”, “aspirations”, “goals”, “aim”, “targets”, “promises” and similar expressions. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements, depending upon, without limitation: • General economic and political conditions in our key markets, government policies and other incidental factors; • Changes in the overall macro-economic parameters including changes inthe currency and interest rates either in India and /or globally; • Ability to successfullyimplement our strategic plan, including research and development efforts; • Changes in laws and regulations that apply tothe pharmaceutical industry and itssuppliers and customers; and • Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry Actual outcomes may varymateriallyfrom those indicated in the applicable forward-looking statements, should one or more of such risks and uncertainties materialize. No representation or warranty, either expressed or implied, is provided in relation to this presentation. This presentation should not be regarded by recipients as a substitute for the exercise of their own judgment. The Company undertakes no obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise. Certain information in this document is not audited or reviewed by an auditor or based on Indian Accounting Standards or internationally accepted accounting principles. The reader should not consider such items as an alternative to the audited financial results or other indicators of the Company’s profit, cash flows or financial performance based on applicable accounting standards. This presentation is property of Glenmark Pharmaceuticals Ltd. Do not alter in any way or reproduce without permission. Summary – Q2 FY27 “Q2 demonstrated the strength and resilience of Glenmark’s base business. We remain on track to deliver our FY27 guidance with Consolidated • Consolidated Revenue of Rs. 42,473 million Revenue • Like-for-Like YoY growth of ~20% continued growth in India, a strong recovery in North America supported by multiple launches, and robust performance across Emerging Markets. RYALTRIS® continues to expand internationally with the recent Brazil launch marking an important milestone. Our partnered innovative oncology pipeline is • India1 business growth of ~14% advancing toward commercialization with the first launch expected Regional • North America2 core business growth of ~31% by the end of FY27. Highlights • EU business growth of 6.2% • EM business growth of 33.2% IGI continues to advance its multispecific oncology pipeline with Phase 1 ISB 2001 data selected for oral presentation at the 2026 American Society of Hematology (ASH) Annual Meeting. We also intend to submit an IND application for ISB 2301 by the end of this • Consolidated R&D at Rs. 3,449 million • EBITDA at Rs. 8,638 million year. Together, these milestones underscore the strength of our Profitability • EBITDA margin of 20.3% innovation platform and position Glenmark for its next phase of • Adj. PAT3 at Rs. 4,852 million sustainable, innovation-led growth and long-term value creation.” • Adj. PAT margin of 11.4% 1. On a like-for-like basis, India formulation business recorded YoY growth of ~14% for Q2 FY27. Glenn Saldanha 2. North America revenue for Q2 FY27 includes deferred out-licensing income recognition for ISB 2001; Net of this, the core business YoY Chairman and Managing Director growth for the North America region was ~31% in Q2 FY27. 3. Adjusting for exceptional items as published in the consolidated results. Glenmark Pharmaceuticals Ltd. Consolidated Revenue – Q2 FY27 Second Quarter ended September 30 First Quarter ended June 30 Rs Mn FY27 FY26 YoY Growth FY27 QoQ Growth India1 13,274 1,651 704.2% 14,321 -7.3% North America2 12,089 44,656 -72.9% 10,974 10.2% Europe 7,920 7,460 6.2% 7,472 6.0% Emerging Markets# 8,769 6,585 33.2% 7,304 20.1% Total 42,052 60,352 -30.3% 40,071 4.9% Other Revenue 421 117 261.0% 114 268.6% Consolidated Revenue 42,473 60,469 -29.8% 40,185 5.7% 1. On a like-for-like basis, India formulation business recorded YoY growth of ~14% for Q2 FY27. 2. North America revenue for Q2 FY27 includes deferred out-licensing income recognition for ISB 2001; Net of this, the core business YoY growth for the North America region was ~31% in Q2 FY27. #Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC) Average conversion rate in 6M FY 2026-27 considered as INR 95.05 / USD 1.00 Average conversion rate in 6M FY 2025-26 considered as INR 86.42 / USD 1.00 USD figures are only indicative Consolidated Revenue – H1 FY27 Six Months ended September 30 Rs Mn FY27 FY26 YoY Growth India 1 27,595 14,050 96.4% North America 2 23,063 52,436 -56.0% Europe 15,392 14,138 8.9% Emerging Markets # 16,073 12,306 30.6% Total 82,122 92,930 -11.6% Other Revenue 536 183 192.7% Consolidated Revenue 82,658 93,113 -11.2% 1. On a like-for-like basis, India formulation business recorded YoY growth of ~15% for H1 FY27. 2. North America revenue for H1 FY27 includes deferred out-licensing income recognition for ISB 2001; Net of this, the core business YoY growth for the North America region was ~25% in H1 FY27. #Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC) Average conversion rate in 6M FY 2026-27 considered as INR 95.05 / USD 1.00 Average conversion rate in 6M FY 2025-26 considered as INR 86.42 / USD 1.00 USD figures are only indicative India Revenue (Rs. million)# Sustained market-beating growth across core therapy franchises 13,274 Expanded leadership positions in Respiratory and Dermatology 1,651 Q2 FY27 Q2 FY26 Increasing strength of Oncology business; 27,595 Glenmark advancing into Top 10 14,050 GCCL posted strong double-digit growth, led by market-leading brands H1 FY27 H1 FY26 # On a like-for-like basis, India formulation business recorded YoY growth of ~14% for Q2 FY27 and ~15% for [Showing first 8,000 characters — download PDF for full document]